Triazole-resistant aspergillus fumigatus in an Israeli patient with chronic cavitary pulmonary aspergillosis due to a novel E306K substitution in Hmg1

Mariana Handelman, Alma Morogovsky, Wei Liu, Ronen Ben-Ami, Nir Osherov

Research output: Contribution to journalArticlepeer-review

Abstract

Triazole resistance in the pathogenic mold Aspergillus fumigatus has increased worldwide, posing a growing therapeutic challenge. Recently, mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase gene (hmg1) have been associated with triazole resistance. Here, we describe a novel E306K triazole resistance-conferring mutation in the HMG-CoA reductase gene from an Israeli patient with chronic cavitary pulmonary aspergillosis (CCPA).

Original languageEnglish
Article numbere01089-21
JournalAntimicrobial Agents and Chemotherapy
Volume65
Issue number10
DOIs
StatePublished - Oct 2021

Keywords

  • Antifungal resistance
  • Aspergillus fumigatus
  • Azole resistance
  • E306K substitution
  • HMG1 mutations
  • Hmg1 resistance mutation
  • Mycology
  • Triazole resistance

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology

Fingerprint

Dive into the research topics of 'Triazole-resistant aspergillus fumigatus in an Israeli patient with chronic cavitary pulmonary aspergillosis due to a novel E306K substitution in Hmg1'. Together they form a unique fingerprint.

Cite this